Xiaowen He

Title: Innovations by Xiaowen He in Antibody Development

Introduction

Xiaowen He is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic use. With a total of 4 patents, his work focuses on enhancing immune responses against tumors.

Latest Patents

One of Xiaowen He's latest patents is titled "ANTI-PD-L1 ANTIBODY AND USE THEREOF." This patent describes an antibody that binds to the PD-L1 protein or CD137 protein, along with an antigen-binding fragment or a variant thereof. Additionally, it includes a bispecific antibody capable of binding to both the PD-L1 protein and the CD137 protein. This bispecific antibody exhibits a strong ability to specifically recognize these proteins and can enhance T-cell activity. The patent also outlines the use of the antibody or its variants in the prevention and treatment of tumors.

Career Highlights

Xiaowen He is currently associated with Oricell Therapeutics Co., Ltd., where he continues to innovate in the field of antibody research. His work has the potential to significantly impact cancer treatment and improve patient outcomes.

Collaborations

Some of his notable coworkers include Huajing Wang and Bohua Li, who contribute to the collaborative efforts in advancing their research and development projects.

Conclusion

Xiaowen He's innovative work in antibody development showcases his commitment to improving therapeutic options for cancer treatment. His contributions are paving the way for future advancements in biotechnology.